Clinical TrialsThe company continues to advance lead asset FB102 towards topline data in celiac disease, and management notes that there have still been no discontinuations to date, suggesting good tolerability.
Competitive AdvantageFB102 shows greater potency than observed with competing IL-15 mAbs like AMGN's ordesekimab (AMG-714) and NVS's CALY-002.
Mechanism Of ActionFB102 is designed to reduce pathogenic NK and T cells by preferentially inhibiting signaling via the low-affinity IL-2/IL-15 receptor complex while sparing immunomodulatory regulatory T cells (Tregs).